Mandate

Vinge has advised Stendörren in connection with a tap issue of SEK 300 million bonds

October 04, 2018 Banking and Finance

Vinge has advised Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with a tap issue of SEK 300 million senior unsecured floating rate bonds. 

The bonds have a tenor of three years and a floating interest rate of three months Stibor plus 4.25 per cent. The proceeds from the subsequent bond issue will be issued for general corporate purposes. Swedbank has acted as Issuing Agent and financial advisor to Stendörren.

In accordance with the terms and conditions, the subsequent bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly.

Vinge also advised Stendörren in connection with the company’s initial bond issue of SEK 350 million on 18 June 2018. A listing prospectus was approved by the Swedish Financial Supervisory Authority on 1 August 2018.

Vinges team consisted of Louise Brorsson Salomon, André Isacson and Fredric Reissmüller.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025